Author:
Rowe J. M.,Chang A. Y. C.,Bennett J. M.
Publisher
Springer Berlin Heidelberg
Reference5 articles.
1. Pedersen-Bjergaard J, Brinker A, J J, et al (1984). Aclarubicin in the Treatment of Acute Non-lymphocytic Leukemia Refractory to Treatment with Daunorubicin and Cytarbine: A Phase II Trial. Cancer Treatment Rep 68: 1233–1238.
2. Bennett JM, Lymann GH, Cassileth PA, et al (1984). A Phase II Trial of VP-16 in Adults with Refractory Acute Myeloid Leukemia: An Eastern Cooperative Oncology Group Study. Am J Clin Oncol 7: 471–473.
3. Schwarzmeier JD, Graninger W, Scheeweiss B et al (1984). In-vitro Sensitivitätstestung leukämischer Zellen gegenüber Etoposide und anderen cytostatischen Substanzen in: Schwarzmeir, Deutsch and Karrer (Eds.), Etoposide (VP-16-213) In Der Therapie Maligner Erkrankungen, Springer-Verlag 24–36, Berlin, Heidelberg, New York.
4. Rowe JM, Chang AYC, Bennett JM: (1988). Aclacinomycin A and Etoposide (VP-16-213): An Effective Regimen in Previously Treated Patients with Refractory Acute Myelogenous Leukemia. Blood 71: 992–996.
5. Rowe JM, Chang AYC, Bennett JM: (1989). Refractory Acute Lymphocytic Leukemia: Response to Aclacinomycin A and VP-16-213. Hematol Oncol 7: 405–410.